A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Anti-tumor Activity of JSKN016HC in Subjects With Advanced Malignant Solid Tumors
Latest Information Update: 20 Mar 2026
At a glance
- Drugs JSKN 016 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Alphamab Oncology
Most Recent Events
- 20 Mar 2026 New trial record